Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 50/100

Form 604 Corporations Act 2001 Section 671B Notice of change of interests of substantial holder To Company Name/Scheme Alterity Therapeutics Limited ACN/ARSN 080 699 065 1. Details of substantial holder (1) Name The Bank

Key Takeaway: The Bank of New York Mellon Corporation has reported a change in its substantial holding of shares in Alterity Therapeutics Limited. As of February 17, 2025, their voting power has decreased from 41.28% to 33.96%, following several transactions involving transfers out and deposits of securities between February 4 and 13, 2025. These changes in interests are required to be reported under the Corporations Act 2001, reflecting alterations in the nature and extent of BNYMC's interest in the company's voting securities.

Market Sentiment Analysis

Full Press Release Details

Corporations Act 2001
Notice of change of interests
of substantial holder
To Company Name/Scheme Alterity Therapeutics Limited
ACN/ARSN 080 699 065
1. Details of substantial holder (1)
Name The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group)
ACN/ARSN (if applicable)
There was a change in the interests of the substantial holder on 17 / February / 2025
The previous notice was given to the company on 04 / February / 2025
The previous notice was dated 03 / February / 2025
2. Previous and present voting power
The total number of votes attached to all the voting
shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in
when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Class of securities (4) Previous notice Present notice
Person's votes Voting power (5) Person's votes Voting power (5)
Ordinary shares 2,266,681,474 41.28% 2,260,546,474* 33.96%*
*See Note 1 in Annexure C
3. Changes in relevant interests
Particulars of each change in, or change in the nature
of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial
holder was last required to give a substantial holding notice to the company or scheme are as follows:
Date of change Person whose relevant interest changed Nature of change (6) Consideration given in relation to change (7) Class and number of securities affected Person's votes affected
See Annexure B
4. Present relevant interests
Particulars of each relevant interest of the substantial
holder in voting securities after the change are as follows:
Holder of relevant interest Registered holder of securities Person entitled to be registered as holder (8) Nature of relevant interest (6) Class and number of securities Person's votes
See Annexure C
5. Changes in association
The persons who have become associates (2) of, ceased
to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests
in the company or scheme are as follows:
Name and ACN/ARSN (if applicable) Nature of association
BNYMC and each Group Entity Each Group Entity is an associate of BNYMC pursuant to section 12(2)(a) of the Corporations Act 2001 (Cth) as each entity is directly or indirectly owned and controlled by BNYMC.
The addresses of persons named in this form are as follows:
Name Address
The Bank of New York Mellon Corporation 240 Greenwich Street, New York, NY 10286 USA
Each Group Entity 240 Greenwich Street, New York, NY 10286 USA
print name Andrew Weiser capacity Attorney-In-Fact
sign here /s/ Andrew Weiser date 18/February/2025
is Annexure A of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate.
The Bank of New York Mellon Corporation
is the ultimate parent company of a corporate group comprised of a large number of operating and holding companies. Details of the entities
directly owned and controlled by The Bank of New York Mellon Corporation are listed below.
print name Andrew Weiser capacity Attorney-In-Fact
sign here /s/ Andrew Weiser date 18/February/2025
of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate
Changes in relevant interests
Date of change Person whose relevant interest changed Nature of Change Consideration given in relation to change Class and number of securities affected (Ordinary Shares) Person's votes affected
4-Feb-2025 The Bank of New York Mellon Transfer Out of securities N/A (9,732,000) (9,732,000)
5-Feb-2025 The Bank of New York Mellon Transfer Out of securities N/A (3,600,000) (3,600,000)
5-Feb-2025 The Bank of New York Mellon Deposit of securities N/A 2,697,000 2,697,000
13-Feb-2025 The Bank of New York Mellon Deposit of securities N/A 4,500,000 4,500,000
Print Name - Andrew Weiser Capacity - Attorney-In-Fact
Sign Here /s/ Andrew Weiser Date - 18 February 2025
is Annexure C of 2 pages referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon
Corporation and its related bodies corporate
Holder of relevant interest Nature of relevant interest Class and number of securities
The Bank of New York Mellon ( BNYM ) Remote Interest Held Under Deposit Agreement Relevant interest under section 608(1)(c) of the Corporations Act 2001 (Cth) arising from BNYM having the limited power to dispose of, or control the exercise of a power to dispose of, securities deposited with or held by BNYM (or its custodian or agent) in its capacity as depositary administering an ADR program for Alterity Therapeutics Limited (Company) under the Deposit Agreement dated January 2, 2008 between the Company, holders of American depositary receipts (ADRs) and BNYM (Deposit Agreement). [*See Note 1 below]. 2,260,545,748 ordinary shares
BNYMC Group (other than BNYM) Relevant interest under section 608(3)(a) and/or section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls. [*See Note 1 and Note 2 below] 2,260,545,748 ordinary shares
Pershing LLC Relevant interest under sections 608(1) of the Corporations Act 2001 (Cth) arising from Pershing LLC being the registered owner of the securities. 726 ordinary shares
BNYMC Group (other than Pershing LLC) Relevant interest under section 608(3)(a) and/or section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely Pershing LLC) in which the voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls. [*See Note 2 below] 726 ordinary shares
Of the total of 2,260,546,474 securities in which the BNYMC Group
has a relevant interest, BNYM has a relevant interest in 2,260,545,748 securities
as depositary for Alterity Therapeutics Limited ADR program administered
under the Deposit Agreement. BNYM's relevant interest in these securities arises as a result of the Deposit Agreement containing rights
for BNYM to dispose of securities held under the ADR program in limited circumstances. Under the Deposit Agreement, ADR holders retain
their rights to dispose of those securities and to give voting instructions for the exercise of voting rights attached to the securities.
BNYMC Group's power to vote or dispose of these securities is qualified accordingly.
2: Each Group Entity is a direct or indirect wholly owned subsidiary of BNYMC, the ultimate parent company. Other than BNYM
in respect of 2,260,545,748 securities (of which BNYM's power to
only dispose of 2,260,545,748 securities is limited - see
Note 1), and Pershing LLC in respect of 726 securities, none of
the BNYMC Group entities are entitled to be registered as holder of the securities and their power to vote or dispose of the securities
is qualified accordingly.
print name Andrew Weiser capacity Attorney-In-Fact
sign here /s/ Andrew Weiser date 18/February/2025

Frequently Asked Questions

Who is the substantial holder for Alterity Therapeutics?

The substantial holder is The Bank of New York Mellon Corporation (BNYMC) and its Group Entities.

When was the recent change in voting power reported?

The recent change in voting power was reported on February 17, 2025.

What was the previous voting power of BNYMC?

BNYMC's previous voting power was 41.28% with 2,266,681,474 votes.

How many votes does BNYMC hold currently?

BNYMC currently holds 2,260,546,474 votes, representing 33.96%.

What is BNYM's role in the securities?

BNYM acts as a depositary for the Alterity Therapeutics Limited ADR program.

Last updated: Feb 19, 2025